Following its notice of interim results, shares inrose by 27% (0.325 per share) yesterday afternoon in anticipation of the results, which will be announced next Monday 24th September.
Deltex is the global leader in its proprietary Oesophageal Doppler Monitoring (ODM) - the only technology to measure blood flow in central circulation in real time.
It is also the only group in the enhanced haemodynamic space, having built a robust and credible evidence base proving the clinical and economic benefits of its core technology, TrueVue Doppler, which has been demonstrated to reduce complications suffered by patients after surgery.
The group aims to provide clinicians with a single platform - called a "haemodynamic workstation" - that offers them a range of technologies.
This will enable the company to partner with healthcare providers to support modern haemodynamic management across the whole hospital.
Houser broker ED and Arden Partners have set target prices ranging between 8.72p and 10.2p.
Deltex Medical is currently in the implementing phase in the UK, USA, Canada and Spain, with distribution arrangements in place in a further 30 countries.
The group has seen a number of new accounts coming onboard in the US market, including a very major account after a rigorous and successful evaluation.
According to a statement by Chairman Nigel Keen, the group has made progress towards profitability and reduced overheads, having “put the Group on a significantly more secure financial footing” after raising £2.0m in additional capital and reducing cash costs by £1.0m.
After a wave of 2018 M&A activity in the biotech space, there is speculation the company could be a potential target - not surprising given its proprietary technology and new promising accounts lined up.
Follow news & updates abouthere:
Five financial stories, trending today in a 70 second podcast, including: MPs have voted to take control of Commons business for a day, in an unprecedented move to try to find a majority for any Brexit option. It means MPs will get a series of votes tomorrow to find out what kind of Brexit they will support, even though Theresa May has said there is no guarantee, she will abide by their decision.
On today's podcast: Live Company Group discuss progress including their new BRICKLIVE Show in Geneva. Bigblu Broadband cover the highlights from their final results released today. Rockfire Resources talks about the high grade copper from their Copper Dome Project in Central Queensland. Botswana Diamonds discuss their interim highlights.
Louis Coetzee, Chief Executive Officer of Kibo Energy (KIBO), addressed shareholders in a letter detailing progress the AIM listed energy company has been making in Sub-Saharan Africa and the UK. “Africa represents a rapidly growing market economy with an acute power deficit”
SP Angel daily look at commodities and miners, featuring: Bushveld Minerals (BMN LN) – Drill results at Brits vanadium project Chaarat Gold* (CGH LN) – Kapan site visit notes: focus on productivity to deliver sustainable cash generation MOD Resources (MOD LN) - Infill drilling at T3 project delivers increased reserves
Oil and gas investment company, Reabold Resources (RBD) shared with investors today that Rathlin Energy, operator of the PEDL 183 license onshore UK, has signed a rig contract for the drilling of the West Newton appraisal well. The well is expected to spud in April 2019.
Five financial stories, trending today in a 70 second podcast, including: Optimism about the business outlook, among Britain’s financial services firms, has fallen at its fastest rate since the 2008 financial crisis, amid concerns about Britain’s exit from the European Union.